SRSF2 and myelodysplastic syndrome: By contrast, isolated +8 MDS patients without mutations in STAG2, SRSF2 and RUNX1 showed a longer time to AML progression (comparable to very low/low-risk MDS patients without +8 classified by IPSS-R) and remained as MDS patients with a low–intermediate IPSS-R risk in terms of OS (Figure 2b,c).